HALOZYME THERAPEUTICS, INC. HALO

Halozyme Therapeutics reported first-quarter revenue of $376.7 million, net income of $150.0 million, and operating income of $184.5 million for the period ending 31 March 2026, while ending the quarter with $309.7 million in cash and equivalents and $2.67 billion in total assets. Diluted earnings per share came in at $1.22 on 122.9 million diluted shares outstanding. The company also disclosed $32.9 million in deferred revenue, with $5.7 million expected to be recognized within the next twelve months. Vertex is on the hook for a $15 million upfront payment under the Hypercon collaboration, plus potential milestone payments and royalties on net product sales. (source: HALO 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1159036/000115903626000068/halo-20260331.htm)

Halozyme’s core business is licensing its proprietary ENHANZE® drug delivery technologies-including the multi-dose pen platform-to partners who embed the technology in injectable therapies. The company’s most visible commercial footprint is Teva’s generic teriparatide injection outside the U.S., which launched in 2020 and continues to generate royalty-bearing sales. Halozyme also lists inventory of $155.5 million, down $27.4 million in the quarter, and spent $25.6 million on R&D during the period. Net cash from operations clocked in at $180.1 million, while capex was a modest $3.7 million. (source: HALO 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1159036/000115903626000068/halo-20260331.htm)

The filing stack shows routine insider share sales-most recently a director’s single share at $137 on 15 June 2026-together with the company’s ongoing Forms 3 and 4 activity, all of which sit inside the broader SEC EDGAR filing index for Halozyme. The SEC submissions JSON and companyfacts JSON confirm the issuer’s identity and active filings but do not add new financial metrics beyond what the 10-Q already discloses. (source: HALO SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1159036; HALO SEC submissions JSON, https://data.sec.gov/submissions/CIK0001159036.json; HALO SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001159036.json)

For the technically minded, the filings route starts at the SEC EDGAR landing page and branches into the issuer’s 10-Q for 31 March 2026, the concurrent 8-K announcing quarterly results, and the 144 notice from 15 May 2026. The filings confirm the issuer, the period, and the disclosed figures; they do not invent new sales data, clinical readouts, or regulatory approvals beyond what the primary documents state. (source: HALO SEC EDGAR index and linked filings, https://www.sec.gov/edgar/browse/?CIK=1159036)

If you want to see how the stock behaves in real time, the TradingView chart for Halozyme on the primary exchange will show the price action and volume, but the SEC filings themselves do not contain intraday or daily price data. The chart is a market mechanism, not a substitute for the company’s financial disclosures, and it reflects liquidity and sentiment rather than the company’s underlying fundamentals. (source: TradingView chart route, issuer-specific ticker)

The evidence set is strong on filings, cash, earnings, and deferred revenue, but it does not include updated product revenues from Teva, Vertex milestone timelines, or fresh pipeline readouts beyond the historical references in the 10-Q. The next meaningful updates would likely arrive in the next 10-Q or an 8-K announcing a new collaboration, an approval, or a milestone payment trigger. Until then, the story is one of steady cash generation, routine insider sales, and deferred revenue that customers are expected to spend over the next year-nothing more, nothing less. (source: HALO 10-Q 2026-03-31, https://www.sec.gov/Archives/edgar/data/1159036/000115903626000068/halo-20260331.htm)